A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Study sponsor: Spruce Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-03Actual
Enrollment · participants27Actual
Source updated2025-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.